Saltar al contenido
Merck
  • Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis.

Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis.

Annals of the rheumatic diseases (2013-10-10)
Yoann Rombouts, Ewoud Ewing, Lotte A van de Stadt, Maurice H J Selman, Leendert A Trouw, André M Deelder, Tom W J Huizinga, Manfred Wuhrer, Dirkjan van Schaardenburg, René E M Toes, Hans U Scherer
RESUMEN

To determine whether anticitrullinated protein antibodies (ACPA) exhibit specific changes in Fc glycosylation prior to the onset of arthritis. Serum samples of patients with ACPA-positive arthralgia (n=183) were collected at baseline and at various time points of follow-up. 105 patients developed arthritis after a median of 12 months (IQR 6-24) and were classified as having either rheumatoid arthritis (RA, n=48) or undifferentiated arthritis (UA, n=57) based on the 1987 American College of Rheumatology (ACR) criteria. ACPA and total serum IgG were isolated by affinity purification and cleaved by trypsin. ACPA-IgG1 Fc-glycopeptides were subsequently analysed by nano-liquid chromatography mass spectrometry and compared to those of total IgG1. At baseline, ACPA-IgG1 and total IgG1 from arthralgia patients displayed similar Fc glycosylation patterns. By contrast, at the onset of arthritis, ACPA exhibited a decrease in galactose residues in RA patients, but not in UA patients. This decrease occurred around 3 months prior to diagnosis and was paralleled by an increase in systemic inflammation (erythrocyte sedimentation rate). Galactosylation of total IgG1 was also decreased in RA, but this did not precede the onset of arthritis. Interestingly, we additionally noted a higher degree of ACPA-IgG1 Fc core fucosylation at baseline as compared with total IgG1, which further increased prior to diagnosis. ACPA display significant changes in Fc galactosylation and fucosylation prior to the onset of RA. These changes towards a more pro-inflammatory phenotype could be involved in driving the disease process.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Ácido fórmico, reagent grade, ≥95%
Sigma-Aldrich
Ácido fórmico, ACS reagent, ≥96%
Sigma-Aldrich
Ácido fórmico, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥98%
Sigma-Aldrich
Ácido fórmico, puriss., meets analytical specifications of DAC, FCC, 98.0-100%
Sigma-Aldrich
Ácido fórmico, ACS reagent, ≥88%
Sigma-Aldrich
Ácido fórmico, ≥95%, FCC, FG
Sigma-Aldrich
Ácido fórmico, JIS special grade, ≥98.0%
Sigma-Aldrich
Formic acid solution, BioUltra, 1.0 M in H2O